Medication leaflets

Active substance

Results for the substance damoctocog alfa pegol

5 results

About this active substance

Damoctocog alfa pegol is an extended half-life recombinant factor VIII used for the treatment and prevention of bleeding episodes in patients with hemophilia A. It replaces the missing or deficient factor VIII, aiding in normal blood clotting.

The medication is administered via intravenous injection, with the dose and frequency determined by the physician based on the patient's weight and the severity of hemophilia. Common side effects include headaches, injection site reactions, and fever.

Damoctocog alfa pegol is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. Patients should also be monitored for potential allergic reactions or the development of factor VIII inhibitors.

This medication is an important option for managing hemophilia A, helping to prevent bleeding complications and improve the quality of life for patients.